Bioquest Corp 10-Q for FY2022 Q3
Bioquest Corp (BQST)
About this 10-Q
Bioquest Corp filed this 10-Q on May 27, 2022, covering the quarter ended January 31, 2022 (FY2022 Q3).
Headline figures
Quarter ended January 31, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net income
- $50.09K
- compared with a net loss of $667.29K a year earlier
- Diluted EPS
- $0.00
- compared with -$0.08 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
Mark One
For
the quarterly period ended
For the transition period from ______ to _______
COMMISSION
FILE NO.
(Exact name of registrant as specified in its charter)
| 5149 | ||||
| (State or Other Jurisdiction of | IRS Employer | Primary Standard Industrial | ||
| Incorporation or Organization) | Identification Number | Classification Code Number |
(Address of principal executive offices)
Phone:
(
(Registrant’s telephone number)
Indicate
by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the
past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐
Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| ☐ | Large, accelerated filer | ☐ | Accelerated filer | |
| ☒ | Smaller reporting company | |||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
Applicable Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five Years.
N/A
Applicable Only to Corporate Registrants
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| N/A |
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
| Class | Outstanding as of May 27, 2022 | |
| Common Stock, $0.001 |
Table of Contents
| PART I | ||
| Item 1. | Condensed Financial Statements | 3 |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 13 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 15 |
| Item 4. | Controls and Procedures | 15 |
| PART II | ||
| Item 1. | Legal Proceedings | 17 |
| Item 1A. | Risk Factors | 17 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 17 |
| Item 3. | Defaults Upon Senior Securities | 17 |
| Item 4. | Mining Safety Disclosures | 17 |
| Item 5. | Other Information | 17 |
| Item 6. | Exhibits | 18 |
| Signatures | 19 |
| 2 |
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
| 3 |
Bioquest Corp.
Condensed Balance Sheets
(Unaudited)
|
January 31, 2022 |
|
April 30, 2021 | |||||
January 31, 2022 | April 30, 2021 | |||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash | $ | $ | ||||||
| Prepaid Expenses | ||||||||
| Total Current Assets | ||||||||
| Total Assets | $ | $ | ||||||
| Liabilities and Stockholders’ Deficit | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable and Accrued Liabilities | $ | $ | ||||||
| Accrued Compensation | ||||||||
| Due to Officers Shareholders | ||||||||
| Accrued Interest | ||||||||
| Convertible Notes Payable | ||||||||
| Notes
Payable, Net of Discount of $ - | ||||||||
| Derivative Liability | ||||||||
| Total Current Liabilities | ||||||||
| Total Liabilities | ||||||||
| Commitments and Contingencies | - | |||||||
| Stockholders’ Deficit | ||||||||
| Common Stock, $ Par Value Authorized; and Issued and Outstanding at January 31, 2022 and April 30, 2021 Respectively | ||||||||
| Additional-Paid-in-Capital | ||||||||
| Accumulated Deficit | ( | ) | ( | ) | ||||
| Total Stockholders’ Deficit | ( | ) | ( | ) | ||||
| Total Liabilities and Stockholders’ Deficit | $ | $ | ||||||
*Derived from Audited Information
See Notes to Unaudited Condensed Financial Statements
| 4 |
Bioquest Corp.
Condensed Statements of Operations
(Unaudited)
| January 31, 2022 | January 31, 2021 | January 31, 2022 | January 31, 2021 | |||||||||||||
Three Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended | |||||||||||||
| January
31, 2022 | January
31, 2021 | January
31, 2022 | January
31, 2021 | |||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||
| Operating Expenses | ||||||||||||||||
| Compensation | ||||||||||||||||
| Stock Compensation Expense | ( | ) | - | |||||||||||||
| Professional Fees | ||||||||||||||||
| General and Administrative Expenses | ( | ) | ||||||||||||||
| Total Operating Expenses | ( | ) | ||||||||||||||
| Operating Income (Loss) | ( | ) | ( | ) | ( | ) | ||||||||||
| Derivative Gain (Expense) | ( | ) | ( | ) | ||||||||||||
| Interest Expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net Income (Loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| - | ||||||||||||||||
| Basic Income (Loss) per Share | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Full Dilutive Income (Loss) Per Share | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Weighted Average Common Shares -Basic | ||||||||||||||||
| Weighted Average Common Shares Fully Diluted | ||||||||||||||||
See Notes to Unaudited Condensed Financial Statements
| 5 |
Bioquest Corp.
Condensed Statement of Changes in Stockholders’ Deficit
For the Three, Six and Nine Months Ended January 31, 2022 and 2021
(Unaudited)
| Shares | $.001 | Payable | Capital | Deficit | Deficit | |||||||||||||||||||
| Common | Par Value | Stock | Additional Paid-In | Accumulated | Stockholders’ | |||||||||||||||||||
| Shares | $.001 | Payable | Capital | Deficit | Deficit | |||||||||||||||||||
| Balance April 30, 2021 | $ | - | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Net Loss for the Three Months Ended July 31, 2021 | - | - | - | ( | ) | ( | ) | |||||||||||||||||
| Shares Issued for Cash | - | |||||||||||||||||||||||
| Balance July 31, 2021 | - | ( | ) | ( | ) | |||||||||||||||||||
| Net Loss for the Three Months Ended October 31, 2021 | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Shares Issued for Settlement of accrued Compensation | - | |||||||||||||||||||||||
| Balance October 31, 2021 | - | ( | ) | $ | ( | ) | ||||||||||||||||||
| Net Income for the Three Months Ended January 31, 2022 | - | - | - | - | $ | |||||||||||||||||||
| Balance January 31, 2022 | $ | $ | - | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||
| Balance April 30, 2020 | $ | $ | 50,000 | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||
| Net Loss for the Three Months Ended July 31, 2020 | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Shares Issued for Cash | - | - | ||||||||||||||||||||||
| Balance July 31, 2020 | $ | $ | 50,000 | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Shares Issued for Cash | - | - | ||||||||||||||||||||||
| Shares Issued for Stock Payable | (50,000 | ) | - | - | ||||||||||||||||||||
| Shares Issued for Employment and Consulting Services | - | - | ||||||||||||||||||||||
| Shares Issued for Prepaid Marketing Services | - | - | ||||||||||||||||||||||
| Net Loss for the Three Months Ended October 31, 2020 | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Balance October 31, 2020 | $ | $ | - | $ | ( | ) | ( | ) | ||||||||||||||||
| Shares Issued for Cash | - | - | ||||||||||||||||||||||
| Shares Issued for Services | - | - | ||||||||||||||||||||||
| Net Loss for the Three Months Ended January 31, 2021 | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Balance January 31, 2021 | $ | $ | - | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||
See Notes to Unaudited Condensed Financial Statements
| 6 |
Bioquest Corp.
Condensed Statements of Cash Flows
(Unaudited)
| January 31, 2022 | January 31, 2021 | |||||||
| Nine Months Ended | Nine Months Ended | |||||||
| January 31, 2022 | January 31, 2021 | |||||||
| Cash Flows from Operating Activities | ||||||||
| Net Loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
| Loss (Gain) on Derivative Liability | ( | ) | ||||||
| Amortization of Debt Discount and Original Issue Discount | ||||||||
| Stock Based Compensation | - | |||||||
| Changes in Operating Assets and Liabilities | ||||||||
| Prepaid Expenses | ||||||||
| Increase in Accounts Payable and Accrued Liabilities | ||||||||
| Increase in Accrued Interest | - | |||||||
| Increase in Accrued Compensation | ||||||||
| Net Cash Used from Operating Activities | ( | ) | ( | ) | ||||
| Cash from Investing Activities | - | - | ||||||
| Cash from Financing Activities | ||||||||
| Sale of Common Stock for Cash | ||||||||
| Stock Issued for Professional Services | - | |||||||
| Issuance of Note Payable | ||||||||
| Net Cash Provided by Financing Activities | ||||||||
| Net Decrease in Cash | ( | ) | ( | ) | ||||
| Beginning Cash | ||||||||
| Ending Cash | $ | $ | ||||||
| Supplemental Information | ||||||||
| Non-Cash Items: | ||||||||
| Shares issued for Extinguishment of Accrued Compensation and Accrued Liabilities | $ | $ | ||||||
See Notes to Unaudited Condensed Financial Statements
| 7 |
BIOQUEST CORP.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
January 31, 2022
(Unaudited)
NOTE 1 - ORGANIZATION AND OPERATIONS
Bioquest
Corp. (the “Company”) was originally incorporated in the State of Nevada on
The Company markets, packages and distributes Hemp-CBD based products and Pharmaceutical based and Government approved products. Our mission is to Create High End, Unique Content and aggregate all relevant CBD content in the Nutraceutical and Pharmaceutical markets. Bioquest Corp. is positioned to generate revenue by bringing new products to the marked, created and marketed by Bioquest Corp. generating immediate revenues and by acquiring established companies who have a presence in CBD industry.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying condensed financial statements are unaudited. These financial statements and notes should be read in conjunction with the audited financial statements and related notes for the years ended April 30, 2021 and 2020.
The accompanying interim condensed financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States under the condensing rules contained within Article 10 of Regulation S-X for interim periods. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States have been condensed or omitted pursuant to such rules. In the opinion of management, the unaudited condensed financial statements and notes have been prepared on the same basis as the audited financial statements for the year ended April 30, 2021 and include all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the Company’s financial position at January 31, 2022 and statements of operations for the three and nine months ended January 31, 2022 and 2021 and cash flows for the cash flows nine months ended January 31, 2022 and 2021. These interim periods are not necessarily indicative of the results to be expected for any other interim period or the full year. The accompanying condensed financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the condensed financial statements. As of January 31, 2022, the Company’s significant accounting policies and estimates, which are detailed in the Company’s audited financial statements for the year ended April 30, 2021, have not changed.
Cash and Cash Equivalents
Cash
equivalents consist of highly liquid investments with maturities of three months or less when purchased. Cash and cash equivalents are
on deposit with financial institutions without any restrictions. As of January 31, 2022, cash equivalents amounted to $
FASB ASC Subtopic 260, Earnings Per Share, provides for the calculation of “Basic” and “Diluted” earnings loss per share. Basic income loss per share is computed by dividing net income loss available to common shareholders by the weighted average number of common shares outstanding for the period. All potentially dilutive securities for loss per share including stock options and stock payable have been excluded from the computations since they would be antidilutive. However, these dilutive securities could potentially dilute earnings per share in the future. The number of potentially dilutive shares were shares as of January 31, 2022, and shares on January 31, 2021.
| 8 |
BIOQUEST CORP.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
January 31, 2022
(Unaudited)
Income Taxes
The Company follows FASB ASC Subtopic 740, Income Taxes, for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled.
Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change.
The Company follows FASB ASC Subtopic 718, Stock Compensation, for accounting for stock-based compensation. The guidance requires that new, modified, and unvested share-based payment transactions, such as grants of stock options and restricted stock, be recognized in the consolidated financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods.
Revenue Recognition
The Company will recognize revenue pursuant to Accounting Standards Codification 606, which requires revenue to be recognized at an amount that reflects the consideration expected to be received in exchange for transferring goods or services to customers. Revenue is recognized when performance obligations are satisfied through the transfer of control of promised goods to the Company’s customers. Control transfers once a customer has the ability to direct the use of, and obtain substantially all the benefits from, the product. This includes the transfer of legal title, physical possession, the risks and rewards of ownership, and customer acceptance.
Revenue will be recognized for the Company’s wholesale customers sales when the Company ships the product from its inventory facility. Revenue will be recognized by the Company for e-commerce sales at the time the merchandise is shipped from our inventory facility. Customers typically receive goods within four days of shipment. Amounts related to shipping and handling that are billed to customers are reflected in revenues, and the related costs are reflected in cost of revenues. Taxes collected from customers and remitted to governmental authorities are presented in the consolidated statements of operations on a net basis. The nature of the Company’s business allows for customers to return previously purchased goods for a return or exchange which may result in a reduction of the Company’s revenues. These sales returns will not be significant to the Company’s revenues in the accompanying financial statements.
| 9 |
BIOQUEST CORP.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
January 31, 2022
(Unaudited)
Fair Value of Financial Instruments
Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820 “Fair Value Measurements and Disclosures” (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) a reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Our company estimates the fair value of financial instruments using the available market information and valuation methods. Considerable judgment is required in estimating fair value. Accordingly, the estimates of fair value may not be indicative of the amounts our company could realize in a current market exchange. As of April 30, 2020, and October 31, 2021, the carrying value of accounts payable and loans that are required to be measured at fair value, approximated fair value due to the short-term nature and maturity of these instruments.
NOTE 3 – GOING CONCERN
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.
As
reflected in the accompanying financial statements, the Company had Cash of $
Bioquest, Corp. markets, packages, and distributes Hemp-CBD based products and Pharmaceutical based and Government approved products. Our mission is to create high end unique content and aggregate all relevant CBD content in the Nutraceutical and Pharmaceutical markets including Medical Grade Products. Bioquest Corp. is positioned to generate revenue by bringing its new and recently developed products to the market and by accruing established companies in the CBD industry, generating immediate revenues. The Company is implementing and marketing to the business-to-business and internet-based E-Commerce to the consumer market. The Company is implementing this plan to achieve profitable and sustainable operations.
The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
NOTE 4 – RELATED PARTY TRANSACTIONS
The
Company settled on September 30, 2021, all amounts of $
| 10 |
BIOQUEST CORP.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
January 31, 2022
(Unaudited)
NOTE 5 – NOTES PAYABLE
The
Company issued convertible notes payable in January and February 2020, in the amount of $
The
Company issued a note payable on September 30, 2020, due in
These notes contain contingent conversion features. The first feature triggers in the event that the Company has a qualified equity offering, as defined, in agreement. If triggered, this allows the holder to convert the principal and any unpaid and accrued interest at a price per share equal to the Discount Rate (as defined in the note agreement) multiplied by the price per share paid by the investors in the qualified financing. The second feature triggers in the event that the Company has an equity financing that does not qualify as a qualified financing. If triggered, this allows the holder to convert the principal and any unpaid and accrued interest into the equity financing security at a rate at the lower of the Discount Rate (as defined in the note agreement) multiplied by the price per share paid by the investors in the equity financing. The third feature triggers in the event that a Sale Event (as defined in the note agreements) occurs. If triggered, this allows the note holders to covert their outstanding principal and any unpaid and accrued interest into common stock of the Company at the Discount Rate (as defined in the note agreement) multiplied by proceeds per share payable in the Sales Event.
Upon maturity, the holders of the notes may elect to convert their unpaid principal and accrued interest into that number of common shares determined by multiplying the Discount Rate (as defined in the note agreement) by the 5 trading day average closing price of the Company’s common stock.
The
expected volatility rate was estimated based on comparison to the volatility of a peer group of companies in similar industries. The
term for the conversion of the notes is based upon the remaining term of the notes. The risk-free interest rate for periods within the
contractual life of the option is based on U.S. Treasury securities. Circumstances may change, and additional data may become available
over time, which could result in changes to these assumptions and methodologies, and thereby materially impact our fair value determination.
The Company recorded an decrease in note discount of $
The following table for the derivative liability summarizes the inputs used for the Black-Scholes pricing model on the nine months ended January 31, 2022.
SUMMARY OF DERIVATIVE LIABILITY USED FOR BLACK-SCHOLES PRICING MODEL
| Note 1 | Note 2 | |||||||
| Exercise price | $ | $ | ||||||
| Risk free interest rate | % | % | ||||||
| Volatility | % | % | ||||||
| Expected term years | ||||||||
| Dividend yield | ||||||||
| 11 |
BIOQUEST CORP.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
January 31, 2022
(Unaudited)
NOTE 6 – STOCKHOLDERS’ DEFICIT
Capital Stock Issued
During
the quarter ended October 31, 2021, the Company issued Reg A shares of common stock for $
Authorized Capital Stock Common Stock
The Company is authorized to issue shares of common stock with a par value of $ per share. As of January 31, 2022, and April 30, 2021, there were and and shares issued and outstanding.
NOTE 7 – COMMITMENTS AND CONTINGENCIES
From time to time the Company may be subject to proceedings, lawsuits, and other claims related to government agencies, operations, shareholders, and contracts. The Company is required to assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of accrual required, if any, for these contingencies is made after analysis of each matter. The required accrual, if any, may change in the future due to new developments in each matter or changes in settlement strategies. The Company does not believe that there are presently any such matters that will have a material adverse effect on its financial condition or results of operations.
NOTE 8 – SUBSEQUENT EVENTS
On
March 1, 2022, the Company entered a convertible note payable for $
The
note is convertible into shares of the Company’s common stock at $ per share. In addition, the Company entered into a consulting
agreement with the same party for $
In addition, we did not identify any additional material events or transactions occurring during subsequent event reporting period that required further recognition or disclosure in these financial statements.
| 12 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements. For this purpose, any statements contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking information includes statements relating to future actions, prospective products, future performance, or results of current or anticipated products, sales and marketing efforts, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management, and other matters. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “continue” and similar expressions or the negative of these similar terms. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking information to encourage companies to provide prospective information about themselves without fear of litigation so long as that information is identified as forward-looking and is accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those projected in the information.
These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that we cannot predict. In evaluating these forward-looking statements, you should consider various factors, including the following: (a) those risks and uncertainties related to general economic conditions, (b) whether we are able to manage our planned growth efficiently and operate profitable operations, (c) whether we are able to generate sufficient revenues or obtain financing to sustain and grow our operations, (d) whether we are able to successfully fulfil our primary requirements for cash, which are explained below under “Liquidity and Capital Resources”. We assume no obligation to update forward-looking statements, except as otherwise required under the applicable federal securities laws. Unless stated otherwise, terms such as the “Company,” “BioQuest,” “we,” “us,” “our,” and similar terms shall refer to BioQuest Corp., Inc., a Nevada corporation, and its subsidiaries.
Results of Operations
Working Capital
| January 31, 2022 | April 30, 2021 | |||||||
| $ | $ | |||||||
| Current assets | 116 | 17,097 | ||||||
| Current liabilities | 393.674 | 1,786,638 | ||||||
| Working capital deficit | (393,558 | ) | (1.769,541 | ) | ||||
Cash Flows
| Nine Months Ended | Nine Months Ended | |||||||
| January 31, 2022 | January 31, 2021 | |||||||
| Cash flows used in operating activities | $ | (65,144 | ) | (188,106 | ) | |||
| Cash flows provided by financing activities | 65,000 | 188,000 | ||||||
| Cash flows used in investing activities | - | - | ||||||
| Net increase (decrease) in cash during period | $ | (144 | ) | $ | (106 | ) | ||
| 13 |
Three and nine months ended January 31, 20221 Compared to the three and nine months ended January 31, 2021
Operating Revenue
The Company had no revenue for the three months and nine months ended January 31,2022 or for the same periods in 2021.
Cost of Revenues
The Company had no cost of revenues for the three and Nine months ended January 31, 2022, or for the same periods in 2021.
Operating Expenses
Compensation was $ -0- and $467,570 for the three months and nine months ended January 31, 2022, compared to $384,000 and $1,024,000 for the same periods in 2021.
Stock Compensation was ($50,000) and $-0- for the three and nine months ended January 31, 2022, compared to $100,000 and $250,000 for the same periods in 2021.
Professional Fees were $2,695 and $74,602 for the three and nine months ended January 31, 2022, as compared to $36.683 and $105,843 for the same periods in 2021and the decrease was limited activity in those periods. to
Stock Compensation for the three months ended January 31, 2022, due to a cancellation of a consulting contract by the Company was $a credit to expense of $50,000 for amounts accrued in previous periods as compared with $100,000 in the same period in the previous year. Stock Compensation for the nine months ended January 31, 2022, was $ -0- compared with $250,000 in the previous year
General and administrative expenses consisted primarily of marketing, product development and general expenses. For the three and nine months ended January 31, 2022, general and administrative expenses were ($5,415) and $45,887 as compared to $43,943 and $98,902 for the same periods in 2021. The difference was from reduced activity in the quarter ended January 31, 2022, and reductions in amounts previously accrued.
Derivative gain (expense) was $1,471 and $75,516 in the three and nine months ended January 31, 2022, and $-0- and ($85,775) for the same periods in the previous year.
Interest expense was $4,098 and $62,347 in the three and nine months ended January 31, 2022, and $16,887 and $18,595 for the same periods in the previous year.
Net Income (Loss)
The Company had net income (loss) $50,094 and ($574,890) for the three months and nine months ended January 31, 2022, as compared to a net loss of ($667,288) and ($1,619,798) for the same periods in the previous year.
Liquidity and Capital Resources
The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. Since its inception, the Company has been funded by related parties through capital investment and borrowing of funds.
As of January 31, 2022, the Company had total current assets of $116. Current assets consisted primarily of cash As of January 31, 2022, the Company had total current liabilities of $393,674 compared to $1,786,868 as of April 30, 2021. Current liabilities consisted primarily of accounts payable and accrued liabilities.
We had negative working capital of $393,558 as of January 31, 2022.
Cash flow from Operating Activities
During the nine months ended January 31, 2022, cash used in operating activities was $65,144 compared to $188,106 for the same period in the preceding year.
Cash flow from Financing Activities
For the nine months ended January 31, 2022, cash provided by financing activities was $ 65,000 compared to
$ 188,000 provided for the same period ended in the preceding year
Quarterly Developments
None.
Subsequent Developments
None.
Going Concern
| 14 |
The accompanying unaudited interim consolidated condensed financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company on a going-concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the consolidated financial statements. The Company has incurred recurring losses from operations and has an accumulated deficit of $. The Company’s ability to continue as a going concern depends upon its ability to obtain adequate funding to support its operations through continuing investments of debt and/or equity by qualified investors/creditors, internally generated working capital and monetization of intellectual property assets. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management is currently pursuing a business strategy which includes raising the necessary funds to finance the Company’s development and marketing efforts.
Critical Accounting Estimates and Policies
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Note 1 to the Financial Statements describes the significant accounting policies and methods used in the preparation of the Financial Statements. Estimates are used for, but not limited to, contingencies and taxes. Actual results could differ materially from those estimates. The following critical accounting policies are impacted significantly by judgments, assumptions, and estimates used in the preparation of the Financial Statements.
We are subject to various loss contingencies arising in the ordinary course of business. We consider the likelihood of loss or impairment of an asset or the incurrence of a liability, as well as our ability to reasonably estimate the amount of loss in determining loss contingencies. An estimated loss contingency is accrued when management concludes that it is probable that an asset has been impaired, or a liability has been incurred and the amount of the loss can be reasonably estimated. We regularly evaluate current information available to us to determine whether such accruals should be adjusted.
We recognize deferred tax assets (future tax benefits) and liabilities for the expected future tax consequences of temporary differences between the book carrying amounts and the tax basis of assets and liabilities. The deferred tax assets and liabilities represent the expected future tax return consequences of those differences, which are expected to be either deductible or taxable when the assets and liabilities are recovered or settled. Future tax benefits have been fully offset by a 100% valuation allowance as management is unable to determine that it is more likely than not that this deferred tax asset will be realized.
Recent Accounting Pronouncements
The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
Off Balance Sheet Arrangements
We have not entered any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
Not applicable to smaller reporting companies.
Item 4. Controls and Procedures.
| 15 |
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and determine that they were not effective.
The following aspects of the Company were noted as potential material weaknesses:
| 1. | We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us for the nine months ended January 31, 2022. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness. |
| 2. | We do not as yet have sufficient resources in our accounting function, which restricts the Company’s ability to gather, analyze and properly review information related to financial reporting in a timely manner. In addition, due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness. |
| 3. | We have inadequate controls to ensure that information necessary to properly record transactions is adequately communicated on a timely basis from non-financial personnel to those responsible for financial reporting. Management evaluated the impact of the lack of timely communication between non–financial personnel and financial personnel on our assessment of our reporting controls and procedures and has concluded that the control deficiency represented a material weakness. |
| 4. | Certain control procedures were unable to be verified due to performance not being sufficiently documented. As an example, some procedures requiring review of certain reports could not be verified due to there being no written documentation of such review. Management evaluated the impact of its failure to maintain proper documentation of the review process on its assessment of its reporting controls and procedures and has concluded deficiencies represented a material weakness. |
In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.
Changes in Internal Controls
Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that no changes occurred in the Company’s internal controls over financial reporting during the quarter ended January 31, 2022, that has materially affected, or is reasonably likely to materially affect, the Company’s internal controls over financial reporting.
| 16 |
PART II – OTHER INFORMATION
Item. 1. Legal Proceedings.
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
Item 1A. Risk Factors.
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Quarterly Issuances:
None.
Subsequent Issuances:
None.
The above securities were issued in reliance on the exemption under Section 4(a)(2) of the Securities Act. These securities qualified for exemption under Section 4(a)(2) since the issuance by us did not involve a public offering. The offerings were not “public offerings” as defined in 4(a)(2) due to the insubstantial number of persons involved in the transactions, manner of the issuance and number of securities issued. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, the investors had the necessary investment intent as required by Section 4(a)(2) since they agreed to and received securities bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(a)(2) of the Securities Act for these transactions.
Item 3. Defaults Upon Senior Securities.
None
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
| 17 |
Item 6. Exhibits
Exhibit Number |
Exhibit Description | |
| 31.1 | Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes- Oxley Act of 2002 | |
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| EX-101.INS | Inline XBRL Instance Document | |
| EX-101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| EX-101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| EX-101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| EX-101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | |
| EX-101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 18 |
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOQUEST CORP, INC. | ||
| BioQuest Corp. | ||
| /s/ Thomas Hemingway | May 27,2022 | |
| Thomas Hemingway, CEO, Principal Executive Officer, Director | Date | |
| /s/ Michael Krall | May 27, 2022 | |
| Michael Krall, President, Director | Date | |
| /s/ David Noyes | May 27, 2022 | |
| David Noyes, CFO, Principal Accounting Officer | Date | |
| /s/ Jeffery Donnell | May 27, 2022 | |
| Jeffery Donnell, Director | Date | |
| /s/ Robert Orbach | May 27, 2022 | |
| Robert Orbach, Director | Date |
| 19 |
Exhibit 31.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14
I, Thomas Hemingway, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of BioQuest Corp.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
| (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
| (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| (b) Any fraud, whether material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: May 27, 2022 | ||
| /s/ Thomas Hemingway | ||
| By: | Thomas Hemingway | |
| Its: | Principal Executive Officer | |
Exhibit 31.2
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14
I, David P. Noyes, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of BioQuest Corp.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
| (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
| (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| (b) Any fraud, whether material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: May 27, 2022 | ||
| /s/ David P. Noyes | ||
| By: | David P. Noyes | |
| Its: | Principal Financial Officer | |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioQuest Corp. (the “Company”) on Form 10-Q for the period ending January 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Hemingway, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| /s/ Thomas Hemingway | |
| By: Thomas Hemingway | |
| Principal Executive Officer | |
| Dated: May 27, 2022 |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioQuest Corp. (the “Company”) on Form 10-Q for the period ending January 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David P. Noyes, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| /s/ David P. Noyes | |
| By: David P. Noyes | |
| Principal Financial Officer | |
| Dated: May 27, 2022 |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.